Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PER Pulse™ Recap
highlights key points presented in Cancer Summaries and Commentaries™: Updates from Singapore: Advances in Personalized Lung Cancer Treatment.
This activity is supported by an educational grant from Merck Sharp & Dohme, Corp.
This activity is designed to update physicians on data that has been recently presented in Singapore so that participants can assess and apply findings to their clinical practices in managing patients with non-small cell lung cancer. Some key trial information was presented at this conference on the use of checkpoint inhibitors alone or in combination to manage advanced forms of these tumors. Additionally, a number of important data sets were also released concerning the use of targeted agents in EGFR-mutated and ALK-rearranged NSCLC.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical oncologists and fellows who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.
At the conclusion of this activity, you should be better prepared to:
Edward Garon, MD
Hematology & Oncology
Ronald Reagan UCLA Medical Center
UCLA Medical Center
Santa Monica, CA
Disclosure: Grant/Research Support: AstraZeneca, BMS, Genentech, Lilly, Merck, Pfizer, Novartis.
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief, Medical Oncology
Associate Director, Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT
Disclosure: Scientific Advisory Boards: Biothera, Diatech, Kolltan, N to 1. Consultant: Lilly, Genentech/Roche, Gilead, Merck, Pfizer. Grant/Clinical Trial Support: Genentech.
The staff of PER®, LLC.
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY